Presentation Archives - Page 4 of 9

Clinical Drug Resistant PDX Models

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. The development of targeted therapies...

Targeted Protein Degradation of Mutant ER-alpha

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription...

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...

Paclitaxel-Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to...

NK Cell Humanized Tumor Models

NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer...

Orthotopic and Metastasis Tumor Models in Rats

Rat tumor models are a better mimic of human pathology compared to mice. The tumor stroma component of rats is...

T-DXd Resistant Tumor Models with ABCG2

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

High-Dimensional Flow Cytometry Platform

High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased...

Immune-Avatar Humanized Tumor Models

To support antitumor efficacy testing and address the challenges of clinical translatability, WuXi AppTec offers extensive panels of immune-avatar humanized...

Knowledge Library